Analysts Offer Predictions for Chimerix, Inc.’s Q2 2024 Earnings (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRX) – Investment analysts at HC Wainwright decreased their Q2 2024 earnings per share estimates for shares of Chimerix in a research note issued to investors on Thursday, May 2nd. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will post earnings of ($0.23) per share for the quarter, down from their previous estimate of ($0.22). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Chimerix’s Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.96) EPS, FY2025 earnings at ($1.07) EPS and FY2026 earnings at ($1.01) EPS.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 41.32%. During the same period last year, the company earned ($0.24) earnings per share.

Several other analysts have also recently issued reports on CMRX. StockNews.com cut shares of Chimerix from a “hold” rating to a “sell” rating in a research note on Friday, May 3rd. Wedbush restated an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research report on Monday, February 12th.

Chimerix Stock Down 1.0 %

Shares of NASDAQ CMRX opened at $0.99 on Monday. The firm has a 50-day simple moving average of $1.03 and a 200-day simple moving average of $1.00. The stock has a market capitalization of $88.73 million, a price-to-earnings ratio of -1.06 and a beta of 1.13. Chimerix has a 52 week low of $0.88 and a 52 week high of $1.57.

Institutional Investors Weigh In On Chimerix

A number of hedge funds have recently modified their holdings of the company. Vance Wealth Inc. acquired a new stake in Chimerix during the fourth quarter worth $46,000. Pale Fire Capital SE acquired a new stake in shares of Chimerix during the 3rd quarter worth about $95,000. Marquette Asset Management LLC raised its holdings in Chimerix by 24.3% in the 1st quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 22,709 shares during the period. Assenagon Asset Management S.A. lifted its position in Chimerix by 167.3% in the third quarter. Assenagon Asset Management S.A. now owns 426,672 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 267,044 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Chimerix by 190.0% during the third quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after buying an additional 387,638 shares during the period. Hedge funds and other institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.